GUMDROP : IMA901 301 A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-Line therapy for Advanced and Metastatic Renal Cell Carcinoma

Created by Nancy Dawson, last modified on Nov 13, 2012

Description:

The purpose of this study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma when added to standard first-line therapy with sunitinib.

Link:

IMA901 301 Study

Site:

Georgetown University Hospital

Principal Investigator:

Dr. Nancy A. Dawson